Can NPC1L1 inhibitors reduce the risk of biliary tract cancer? Evidence from a mendelian randomization study.

Hao DongRong ChenJiafeng WangNingli ChaiEnqiang Linghu

Published in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2024)

This MR study suggests a causal link between NPC1L1 inhibition and reduced BTC risk. NPC1L1 inhibitors, like ezetimibe, show potential for chemoprevention in precancerous BTC patients, requiring further clinical investigation.

Keyphrases

ejection fraction
end stage renal disease
newly diagnosed
magnetic resonance
squamous cell carcinoma
magnetic resonance imaging
prognostic factors
computed tomography
risk assessment
childhood cancer